Statement: 30% of the primary trial participants had an increased level of CECs after 42 days of treatment.
Primary_evidence: Outcome Measurement:    Fraction of Patients With Increased Levels of Circulating Endothelial Cells   An exact 95% confidence interval (CI) will be calculated for the CEC response rate. With 26 patients, this CI will be no wider than 40% (e.g., if 13 of 26 patients respond, the CI is 30% to 70%).   Time frame: After 3 weeks of treatment Results 1:    Arm/Group Title: Treatment (Cediranib Maleate)   Arm/Group Description: Patients receive oral AZD2171 once daily for 42 days. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 26   Measure Type: Number   Unit of Measure: percentage of participants  30